| General Information | |
|---|---|
| ZINC ID | ZINC000045285034 |
| Molecular Weight (Da) | 398 |
| SMILES | Cc1c(C(=O)NC2CCCCCC2)nn(-c2ccc(F)cc2F)c1-n1cccc1 |
| Molecular Formula | C22F2N4O1 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 106.531 |
| HBA | 2 |
| HBD | 1 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 29 |
| LogP | 5.133 |
| Activity (Ki) in nM | 562.341 |
| Polar Surface Area (PSA) | 51.85 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 0.98017537 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 16 |
| Fraction csp3 | 0.36 |
| Ilogp | 4.19 |
| Xlogp3 | 5.15 |
| Wlogp | 5.54 |
| Mlogp | 4.29 |
| Silicos-it log p | 3.81 |
| Consensus log p | 4.6 |
| Esol log s | -5.63 |
| Esol solubility (mg/ml) | 0.000927 |
| Esol solubility (mol/l) | 0.00000233 |
| Esol class | Moderately |
| Ali log s | -5.98 |
| Ali solubility (mg/ml) | 0.000413 |
| Ali solubility (mol/l) | 0.00000104 |
| Ali class | Moderately |
| Silicos-it logsw | -6.41 |
| Silicos-it solubility (mg/ml) | 0.000154 |
| Silicos-it solubility (mol/l) | 0.00000038 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -5.07 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 0 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.22 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -6.032 |
| Logd | 4.123 |
| Logp | 5.003 |
| F (20%) | 0.001 |
| F (30%) | 0.002 |
| Mdck | - |
| Ppb | 96.14% |
| Vdss | 0.856 |
| Fu | 3.60% |
| Cyp1a2-inh | 0.468 |
| Cyp1a2-sub | 0.443 |
| Cyp2c19-inh | 0.932 |
| Cyp2c19-sub | 0.424 |
| Cl | 2.597 |
| T12 | 0.056 |
| H-ht | 0.671 |
| Dili | 0.917 |
| Roa | 0.25 |
| Fdamdd | 0.921 |
| Skinsen | 0.25 |
| Ec | 0.003 |
| Ei | 0.012 |
| Respiratory | 0.537 |
| Bcf | 1.551 |
| Igc50 | 4.006 |
| Lc50 | 4.615 |
| Lc50dm | 5.796 |
| Nr-ar | 0.024 |
| Nr-ar-lbd | 0.006 |
| Nr-ahr | 0.786 |
| Nr-aromatase | 0.974 |
| Nr-er | 0.374 |
| Nr-er-lbd | 0.005 |
| Nr-ppar-gamma | 0.947 |
| Sr-are | 0.778 |
| Sr-atad5 | 0.017 |
| Sr-hse | 0.314 |
| Sr-mmp | 0.789 |
| Sr-p53 | 0.923 |
| Vol | 398.663 |
| Dense | 0.999 |
| Flex | 0.208 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 0 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 1 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | - |
| Toxicophores | 2 |
| Qed | 0.648 |
| Synth | 2.547 |
| Fsp3 | 0.364 |
| Mce-18 | 54.267 |
| Natural product-likeness | -1.814 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Accepted |